Story
Oxford BioMedica Shares Plunge After Slashing Full-Year Revenue Forecast

Shares of Oxford BioMedica (LSE:OXB) plummeted more than 18% in morning trading after the company issued a significant downward revision to its full-year 2026 revenue guidance, surprising investors.
Guidance Cut
The contract development and manufacturing organization (CDMO) now anticipates full-year revenues in the range of £180 million to £200 million. This is a substantial reduction from its previous forecast of £220 million to £240 million.
Oxford BioMedica attributed the approximately £40 million cut at the midpoint to a "short-term shift in client ordering behaviour." The revision represents a significant blow to management's credibility, as the company had reaffirmed the higher guidance as recently as March 2026.
Investor Confidence Shaken
AdThe sudden reversal is particularly jarring for the market because management had previously stated that 60% of the original revenue forecast was already secured through contracted client orders. Today's announcement forces a reassessment of the company's near-term growth trajectory and forecasting accuracy.
The sell-off appeared to be driven entirely by the company-specific news. Broader market conditions were neutral, with no major economic data releases or competitor announcements identified as contributing factors, according to Investing.com.
Market Reaction
The stock fell as much as 18.4% to a session low of 441.5 pence. The sharp decline pushes the share price near its 52-week low of 430p, a stark contrast to its 52-week high of 950p.
Read next
More on Stocks
FTC Orders Walmart, Uber, Delta to Disclose Data on Personalized Pricing
The U.S. Federal Trade Commission is demanding nine major companies, including leading retail, travel, and gig economy firms, to provide information on how they use consumer data for setting individual prices and wages.

Google Launches Gemini 4 Carbon AI Model to Bolster Cybersecurity Capabilities
Alphabet's Google has unveiled Gemini 4 Carbon, its latest AI model specifically designed for advanced cybersecurity tasks like vulnerability detection and secure code generation. The launch escalates competition with rivals OpenAI and Anthropic in the enterprise AI market.

Oracle Shares Surge After Unveiling $225 Billion Revenue Target for 2030
Oracle stock rose sharply after the company presented a long-term financial outlook targeting at least $225 billion in annual revenue by fiscal 2030, driven by its expanding AI infrastructure business.

DOJ Scrutinizes Nvidia's $12.9B Hugging Face Deal Amid Broader Antitrust Probe, Sources Say
The U.S. Department of Justice is reportedly examining Nvidia's planned $12.93 billion acquisition of AI platform Hugging Face as part of a wider, ongoing antitrust investigation into the chipmaker's market conduct.